Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma

NCT00295815 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00295815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00295815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2006
Completion date
May 31, 2014
Enrollment
397 (actual)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma